CRISPR

CRISPR1-magi2a

ID

ZDB-CRISPR-190918-1

Name

CRISPR1-magi2a

Previous Names

None

Target

magi2a (1)

Sequence

5' - GGGTTGTCCAGGGGTCCGAG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The first two "G" were added to improve binding.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
cl604	magi2a
cl605	magi2a
cl606	magi2a
cl607	magi2a

Expression

Gene expression in Wild Types + CRISPR1-magi2a

No data available

Phenotype

Phenotype resulting from CRISPR1-magi2a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-magi2a

Phenotype	Fish	Conditions	Figures
renal glomerulus cell decreased amount, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 3 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl604/cl604; mi1000Tg	chemical treatment by environment: tacrolimus hydrate	Fig. 4 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 2, Fig. 4 from Jobst-Schwan et al., 2019
orbital region edematous, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 4 from Jobst-Schwan et al., 2019
renal glomerulus distended, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 3 from Jobst-Schwan et al., 2019
whole organism viability, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 2 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl604/cl604; mi1000Tg	chemical treatment by environment: Y-27632	Fig. 4 from Jobst-Schwan et al., 2019
mesonephric podocyte podocyte foot flattened, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 3 from Jobst-Schwan et al., 2019
peritoneum edematous, exacerbated	magi2a^cl604/cl604; mi1000Tg	chemical treatment by environment: prednisolone	Fig. 4 from Jobst-Schwan et al., 2019
mesonephric podocyte fenestrated blood vessel endothelium structure, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 3 from Jobst-Schwan et al., 2019
peritoneum edematous, exacerbated	magi2a^cl604/cl604; mi1000Tg	chemical treatment by environment: dexamethasone	Fig. 4 from Jobst-Schwan et al., 2019
glomerular capillary distended, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 3 from Jobst-Schwan et al., 2019
urine protein polypeptide chain present, abnormal	magi2a^cl604/cl604; mi1000Tg	standard conditions	Fig. 1 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl604/cl604; mi1000Tg	chemical treatment by environment: lysophosphatidic acids	Fig. 4 from Jobst-Schwan et al., 2019
whole organism viability, abnormal	magi2a^cl605/cl605; mi1000Tg	standard conditions	Fig. 2 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl605/cl605; mi1000Tg	standard conditions	Fig. 2 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl606/cl606; mi1000Tg	standard conditions	Fig. 2 from Jobst-Schwan et al., 2019
whole organism magi2a expression decreased amount, abnormal	magi2a^cl607/cl607; mi1000Tg	standard conditions	Fig. S5 from Jobst-Schwan et al., 2019
peritoneum edematous, abnormal	magi2a^cl607/cl607; mi1000Tg	standard conditions	Fig. 2 from Jobst-Schwan et al., 2019

Citations